2026-04-29T06:15:45Zhttps://repisalud.isciii.es/rest/oai/requestoai:repisalud.isciii.es:20.500.12105/187462024-09-21T22:16:35Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16927
Repisalud
author
Martínez-Esteban, María Dolores
author
Vázquez-Sánchez, Teresa
author
Pozo-Álvarez, Rafael
author
Moreno-Ortiz, Alicia
author
Alonso-Titos, Juana
author
Martín-Reyes, Guillermo
author
Ruiz-Esteban, Pedro
author
Gaitán-Román, Daniel
author
Hernández, Domingo
2024-02-27T15:10:24Z
2024-02-27T15:10:24Z
2022-08-23
http://hdl.handle.net/10668/20272
http://hdl.handle.net/20.500.12105/18746
35999504
10.1186/s12882-022-02919-z
1471-2369
BMC nephrology
The association between cardiac complications, such as heart failure (HF), and chronic kidney disease (CKD) is well known. In this study, we examined the effectiveness and safety of treatment with neprilysin inhibition in patients with advanced chronic kidney disease (stage 3b-4). This single-centre, longitudinal, retrospective study of 31 months duration involved consecutive patients with CKD and HF with a reduced ejection fraction (HFrEF) who started treatment with sacubitril/valsartan. Glomerular filtration rate (GFR), cardiovascular risk factors, proteinuria, potassium, echocardiographic parameters and admissions for heart failure were analysed. The study comprised 25 patients with a median age of 73.2 ± 5.9 years. The most frequent aetiology of heart failure was ischemic heart disease. The median GFR was 29.4 ± 8.3 ml/min/1.73 m2 and the left ventricular ejection fraction (LVEF) 36.4 ± 8.9%. The GFR improved after initiating the treatment (F = 3.396, p = 0.019), as did the LVEF at one year of follow-up (p = 0.018). The number of visits to the emergency department for heart failure was also reduced. No patients needed to start renal replacement therapy. This study shows that sacubitril/valsartan may play a beneficial role in patients who have advanced CKD and HFrEF, with a satisfactory safety profile.
eng
Chronic kidney disease
Glomerular filtration rate
Heart failure
Neprilysin inhibitor
Reduced ejection fraction
Cardio-renal benefits of sacubitril/valsartan in patients with advanced chronic kidney disease: experience in daily clinical practice.
research article